Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9241
Peer-review started: June 2, 2022
First decision: June 18, 2022
Revised: June 27, 2022
Accepted: August 6, 2022
Article in press: August 6, 2022
Published online: September 16, 2022
Processing time: 91 Days and 21.3 Hours
Hematopoietic stem cell transplantation (HSCT)-sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease, is a clinical syndrome characterized by symptoms, such as right upper quadrant pain, jaundice, fluid retention, and hepatomegaly, and is caused by pre-treatment-related hepatotoxicity during the early stages after HSCT. Clinical diagnosis of HSCT-SOS is based on the revised Seattle or Baltimore standards. The revised standard by the European Society for Bone Marrow Transplantation in 2016 has good practicability and can be used in combination with these two standards. Eight studies have shown the value of liver stiffness measurement (LSM) in the early diagnosis of HSCT-SOS. Four studies investigated LSM specificity and sensitivity for the early diagnosis of HSCT-SOS. LSM can distinguish SOS from other post-HSCT complications, enabling a clear differential diagnosis. It has been shown that median LSM of patients with SOS is significantly higher than that of patients with other treat
Core Tip: Clinical diagnosis of hematopoietic stem cell transplantation (HSCT)-sinusoidal obstruction syndrome (SOS) is based on the revised Seattle or Baltimore standards. Eight studies have shown the value of liver stiffness measurement (LSM) in the early diagnosis of HSCT-SOS. Four studies investigated the specificity and sensitivity of LSM for the early diagnosis of HSCT-SOS. Therefore, LSM can distinguish SOS from other post-HSCT complications, enabling a clear differential diagnosis. The early diagnosis of SOS is beneficial in preventing severe HSCT complications.
